New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.
A new imaging technology to grade tumour biopsies has been developed by a team of scientists led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London.
Publishing their results today in the journal Convergent Science Physical Oncology, they describe how their new method promises to significantly reduce the subjectivity and variability in grading the severity of cancers.
[Digistain] is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis.Professor Chris Phillips
Nearly all cancers are still diagnosed by doctors taking a sample of the tumour, a so-called biopsy, then slicing it thinly and staining it with two vegetable dyes used for more than 100 years. They look at this ‘H+E stained’ sample under a microscope and then judge the severity of the disease by eye alone.
Life-changing treatment decisions have to be based on this ‘grading’ process, yet it is well known that different practitioners given the same slice will only agree on its grade about 70% of the time, resulting in an overtreatment problem.
The team’s new ‘Digistain’ technology addresses this problem by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer. In particular, they measure the ‘nuclear-to-cytoplasmic-ratio’ (NCR): a recognized biological marker for a wide range of cancers.
Lead author Professor Chris Phillips, from the Department of Physics at Imperial, said: “Our machine gives a quantitative ‘Digistain index’ (DI) score, corresponding to the NCR, and this study shows that it is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis. “
In the experiment reported today, the team carried out a double-blind clinical pilot trial using two adjacent slices taken from 75 breast cancer biopsies. The first slice was graded by clinicians as usual, using the standard H+E protocol. It was also used to identify the so-called ‘region of interest’ (RoI), i.e. the part of the slice containing the tumour.
The team then used the Digistain imager to get a DI value averaged over the corresponding RoI on the other, unstained slice, and ran a statistical analysis on the results.
Professor Phillips said: “Even with this modest number of samples, the correlation we saw between the DI score and the H+E grade would only happen by chance 1 time in 1400 trials. The strength of this correlation makes us extremely optimistic that Digistain will be able to eliminate subjectivity and variability in biopsy grading.”
Proving its worth
The NCR factor that Digistain measures is known to be common to a wide range of cancers, as it occurs when the reproductive cell cycle gets disrupted in the tumour and cell nuclei get distorted with rogue DNA. It is likely that in the long run, Digistain could help with the diagnosis of all different types of cancer.
At a practical level, the researchers say that the Digistain imaging technology can easily and cheaply be incorporated into existing hospital labs, and be used by their staff. Professor Philips added: “It’s easy to prove its worth by checking it with the thousands of existing biopsy specimens that are already held in hospital archives. Together these facts will smooth the path into the clinic, and it could be saving lives in only a couple of years.”
The Latest on: Cancer diagnosis
via Google News
The Latest on: Cancer diagnosis
- HN Ananth Kumar was diagnosed with lung cancer in May on November 12, 2018 at 7:35 pm
HN Ananth Kumar was diagnosed with lung cancer in May, said doctors who treated him during his last days in Bengaluru. He was brought to Sri Shankara Cancer Foundation and Research Centre in South ... […]
- CDS tool improves reader diagnosis of bladder cancer response to treatment on November 12, 2018 at 4:31 pm
A decision support tool can help physicians better diagnose bladder cancer treatment response on CT, according to an Nov. 10 study published in Academic Radiology. Currently, there are no dependable m... […]
- NeNe Leakes Says Husband Gregg Leakes 'Never Wanted to Go to the Doctor' Before Cancer Diagnosis on November 12, 2018 at 10:41 am
Before Gregg Leakes was diagnosed with stage 3 colon cancer, the Real Housewives of Atlanta star, 63, had avoided going to the doctor for years despite his wife NeNe Leakes’ repeated attempts ... […]
- In the C-Suite: Leigh Howe wants anyone diagnosed with cancer to know about this treatment on November 12, 2018 at 4:38 am
An estimated 1.7 million new cases of cancer will be diagnosed this year in the U.S. alone, according to the National Center Institute. That's why hospitals, research institutions and clinics like the ... […]
- Global Liquid Biopsy Markets 2019-2023 By Cancer Type By Diagnosis, Monitoring & Recurrence Testing - ResearchAndMarkets.com on November 12, 2018 at 3:36 am
The "Liquid Biopsy Markets By Cancer Type By Diagnosis, Monitoring & Recurrence Testing. 2019-2023 W. Historical Data Including Screening Market Potential Size With Executive And Consultant Guides" re... […]
- Breast cancer diagnosis changes surgeon's patient approach on November 12, 2018 at 1:09 am
"You don't really appreciate what patients go through when they're diagnosed with cancer," said Dr. Sharon Ben-Or. "It's like a death," she added. "You go through all the different phases of grief." A... […]
- Grey's Anatomy recap: A death, a cancer diagnosis, and a breakup on November 9, 2018 at 2:00 am
If the majority of the Grey’s Anatomy cast hadn’t been absent from the episode, I would have sworn it was the fall finale. We experienced three shocking moments, none of which were happy-go-lucky. Peo... […]
- ABCD: After Breast Cancer Diagnosis on November 8, 2018 at 10:08 pm
Organization's mission statement: ABCD: After Breast Cancer Diagnosis nurtures hope and restores confidence in anyone affected by a breast cancer diagnosis. History of the organization: In 1992, Melod... […]
- Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis on November 8, 2018 at 12:24 pm
Veracyte, Inc. VCYT, +5.92% announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in ... […]
via Bing News